Galapagos NV (GLPG) Stock Rating Upgraded by BidaskClub
Galapagos NV (NASDAQ:GLPG) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
Other analysts have also issued research reports about the company. Janney Montgomery Scott lowered Galapagos NV from a “buy” rating to a “sell” rating in a research report on Monday, April 24th. Nomura dropped their price objective on Galapagos NV from $108.00 to $121.00 and set a “buy” rating on the stock in a report on Thursday, June 22nd. Stifel Nicolaus raised their price objective on Galapagos NV from $65.00 to $83.00 and gave the stock a “hold” rating in a report on Monday, May 1st. Zacks Investment Research lowered Galapagos NV from a “buy” rating to a “hold” rating in a report on Monday, April 24th. Finally, Instinet reaffirmed a “buy” rating and set a $108.00 price objective (down previously from $121.00) on shares of Galapagos NV in a report on Thursday, June 22nd. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Galapagos NV presently has a consensus rating of “Buy” and an average target price of $96.14.
Shares of Galapagos NV (GLPG) traded down 1.12% during midday trading on Thursday, hitting $86.43. The stock had a trading volume of 219,221 shares. Galapagos NV has a 52-week low of $53.01 and a 52-week high of $94.88.
Several institutional investors have recently bought and sold shares of the stock. Bogle Investment Management L P DE purchased a new position in shares of Galapagos NV during the first quarter worth approximately $368,000. Airain ltd bought a new stake in Galapagos NV during the first quarter valued at $237,000. Wellington Management Group LLP increased its stake in Galapagos NV by 9.5% in the first quarter. Wellington Management Group LLP now owns 458,088 shares of the biotechnology company’s stock valued at $39,483,000 after buying an additional 39,729 shares during the last quarter. Bank of Montreal Can increased its stake in Galapagos NV by 8,736.4% in the first quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 1,922 shares during the last quarter. Finally, Driehaus Capital Management LLC bought a new stake in Galapagos NV during the first quarter valued at $942,000. Institutional investors and hedge funds own 20.73% of the company’s stock.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.